Burcon NutraScience Corporation

What they do

Burcon develops novel plant-based protein ingredients and related technologies, primarily focusing on canola and pea proteins. The company operates through its equity method investment in Merit Functional Foods, which is not consolidated in Burcon's financial statements. Burcon's operations are centered on research and development, patent portfolio management, and licensing its proprietary technologies.

Revenue drivers

• Equity investment in Merit Functional Foods — Burcon's primary revenue driver is its significant equity method investment in Merit, which is involved in functional food ingredients. However, Merit's financials are not consolidated, and Burcon's income from this investment is limited.

Recent performance

For the fiscal year ended March 31, 2022, Burcon reported a net loss of $3.5 million. The company had cash and cash equivalents of $8.2 million. R&D expenses totaled $1.4 million, and G&A expenses were $2.1 million. The company has no revenue from product sales, as it is pre-commercial.

Strategy

Burcon's strategy centers on advancing its plant-protein technology through R&D and leveraging its equity stake in Merit to commercialize its innovations. The company focuses on building and protecting its intellectual property portfolio. It also seeks to raise capital to fund operations and support Merit's growth, though it faces potential regulatory hurdles with the SEC regarding Merit's financial statements.

Risks

• SEC non-compliance risk — Burcon failed to file Merit's audited financial statements as required by Rule 3-09, and the SEC has not granted a waiver, which could lead to enforcement actions or delisting from Nasdaq.
• Dependence on Merit — Burcon's future prospects are heavily tied to the success of Merit, but it lacks contractual rights to control Merit's audit standards or access its financials in a manner compliant with U.S. GAAP.
• Pre-commercial stage — Burcon has no product revenue, and its viability depends on continued funding and successful commercialization of its technologies, which may not materialize.
• Capital constraints — The company's limited cash reserves ($8.2 million) may be insufficient to sustain operations without additional financing, and regulatory issues could hamper its ability to raise capital in the U.S.

Outlook

Management expects to continue R&D and support Merit's growth, but the near-term outlook is uncertain due to the SEC non-compliance issue that could affect Nasdaq listing and capital raising. The company may be unable to complete a public offering in the U.S. until resolved.